Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686998 · ClinicalTrials.gov registry record · Phase 2
Phase IIA Study in Patients With Schizophrenia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00686998: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00686998 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00686998, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Primary Outcome
PANSS total score, sum of 30 item scores (each on a 0 to 7 scale), assesses positive and negative symptoms of psychopathology on a continuous scale from 0 (the best) to 210 (the worst). Day 28 value was calculated using last observation carried forward (LOCF). Change from baseline was calculated as Day 28 value minus baseline value.
Interventions
- DRUG Placebo
- DRUG Olanzapine
- DRUG AZD2624
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
What the finished NCT00686998 record still lists
NCT00686998 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00686998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00686998 about?
NCT00686998 is a clinical study titled "Phase IIA Study in Patients With Schizophrenia". This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
What is the current status of trial NCT00686998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00686998?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG), AZD2624 (DRUG).
Who is sponsoring clinical trial NCT00686998?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00686998's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia